Co-Target(s) Information
Target General Information | Top | ||||
---|---|---|---|---|---|
Target ID | T14597 | Target Info | |||
Target Name | Erbb2 tyrosine kinase receptor (HER2) | ||||
Synonyms |
p185erbB2; Tyrosine kinase-type cell surface receptor HER2; Receptor tyrosine-protein kinase erbB-2; Proto-oncogene c-ErbB-2; Proto-oncogene Neu; NGL; NEU; Metastatic lymph node gene 19 protein; MLN19; MLN 19; HER2; CD340
Click to Show/Hide
|
||||
Target Type | Successful Target | ||||
Gene Name | ERBB2 | ||||
Biochemical Class | Kinase | ||||
UniProt ID |
Co-Targets of This Target | Top | |||||
---|---|---|---|---|---|---|
Co-Target Name | Epidermal growth factor receptor (EGFR) | Successful Target | ||||
UniProt ID | EGFR_HUMAN | |||||
Gene Name | EGFR | |||||
Synonyms |
Receptor tyrosine-protein kinase erbB-1; Proto-oncogene c-ErbB-1; HER1; ERBB1; ERBB
Click to Show/Hide
|
|||||
Representative Drug(s) | HM-78136B | Drug Info | IC50 = 0.078 nM | Click to Show More | [1] | |
2 | HKI-272 | Drug Info | IC50 = 0.08 nM | [2] | ||
3 | CI-1033 | Drug Info | Ki = 0.11 nM | [3] | ||
4 | BIBW 2992 | Drug Info | IC50 = 0.19 nM | [4] | ||
5 | TAK-285 | Drug Info | IC50 = 1 nM | [5] | ||
6 | Dacomitinib | Drug Info | IC50 = 1.8 nM | [6] | ||
7 | Lapatinib | Drug Info | IC50 = 1.8 nM | [7] | ||
8 | CUDC-101 | Drug Info | IC50 = 2.4 nM | [8] | ||
9 | AZD8931 | Drug Info | IC50 = 4 nM | [9] | ||
10 | Varlitinib | Drug Info | IC50 = 7 nM | [11] | ||
11 | BMS-599626 | Drug Info | IC50 = 32 nM | [16] | ||
Co-Target Name | Erbb4 tyrosine kinase receptor (Erbb-4) | Successful Target | ||||
UniProt ID | ERBB4_HUMAN | |||||
Gene Name | ERBB4 | |||||
Synonyms |
Tyrosine kinase-type cell surface receptor HER4; Receptor tyrosine-protein kinase erbB-4; Proto-oncogene-like protein c-ErbB-4; P180erbB4; HER4
Click to Show/Hide
|
|||||
Representative Drug(s) | Varlitinib | Drug Info | IC50 = 4 nM | Click to Show More | [10] | |
2 | CI-1033 | Drug Info | IC50 = 10 nM | [13] | ||
3 | Dacomitinib | Drug Info | IC50 = 74 nM | [17] | ||
4 | BMS-599626 | Drug Info | IC50 = 190 nM | [19] | ||
5 | TAK-285 | Drug Info | IC50 = 260 nM | [20] | ||
6 | Lapatinib | Drug Info | IC50 ~ 1000 nM | [21] | ||
Co-Target Name | Histone deacetylase (HDAC) | Successful Target | ||||
UniProt ID | HDAC1_HUMAN; HDAC2_HUMAN; HDAC3_HUMAN; HDAC4_HUMAN; HDAC5_HUMAN; HDAC6_HUMAN; HDAC7_HUMAN; HDAC8_HUMAN; HDAC9_HUMAN; HDA10_HUMAN; HDA11_HUMAN | |||||
Gene Name | NO-GeName | |||||
Synonyms |
Human histone deacetylase
Click to Show/Hide
|
|||||
Representative Drug(s) | CUDC-101 | Drug Info | IC50 = 4.4 nM | [8] | ||
Co-Target Name | Histone deacetylase 1 (HDAC1) | Successful Target | ||||
UniProt ID | HDAC1_HUMAN | |||||
Gene Name | HDAC1 | |||||
Synonyms |
RPD3L1; HD1
Click to Show/Hide
|
|||||
Representative Drug(s) | CUDC-101 | Drug Info | IC50 = 4.5 nM | [8] | ||
Co-Target Name | Inosine-5'-monophosphate dehydrogenase (IMPDH) | Successful Target | ||||
UniProt ID | IMDH1_HUMAN; IMDH2_HUMAN | |||||
Gene Name | NO-GeName | |||||
Representative Drug(s) | Merimepodib | Drug Info | IC50 = 7 nM | [12] | ||
Co-Target Name | Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) | Successful Target | ||||
UniProt ID | IMDH2_HUMAN | |||||
Gene Name | IMPDH2 | |||||
Synonyms |
IMPDH-II; IMPDH 2; IMPD2; IMPD 2; IMP dehydrogenase 2
Click to Show/Hide
|
|||||
Representative Drug(s) | Merimepodib | Drug Info | IC50 = 10 nM | [14] | ||
Co-Target Name | Farnesoid X-activated receptor (FXR) | Successful Target | ||||
UniProt ID | NR1H4_HUMAN | |||||
Gene Name | NR1H4 | |||||
Synonyms |
Retinoid X receptor-interacting protein 14; RXR-interacting protein 14; RIP14; Nuclear receptor subfamily 1 group H member 4; HRR1; Farnesol receptor HRR-1; FXR; Bile acid receptor; BAR
Click to Show/Hide
|
|||||
Representative Drug(s) | Bevacizumab + Trastuzumab | Drug Info | IC50 = 18.3 nM | [15] | ||
Co-Target Name | LCK tyrosine protein kinase (LCK) | Successful Target | ||||
UniProt ID | LCK_HUMAN | |||||
Gene Name | LCK | |||||
Synonyms |
p56-LCK; Tyrosine-protein kinase Lck; T cell-specific protein-tyrosine kinase; Proto-oncogene tyrosine-protein kinase LCK; Proto-oncogene Lck; Protein YT16; Lymphocyte cell-specific protein-tyrosine kinase; Leukocyte C-terminal Src kinase; LSK; LCK p59-Fyn; LCK Protooncogene Syn
Click to Show/Hide
|
|||||
Representative Drug(s) | Dacomitinib | Drug Info | IC50 = 94 nM | [17] | ||
Co-Target Name | Proto-oncogene c-Src (SRC) | Successful Target | ||||
UniProt ID | SRC_HUMAN | |||||
Gene Name | SRC | |||||
Synonyms |
pp60c-src; Tyrosine kinase (pp60(src)); Src tyrosine kinase; SRC1; Proto-oncogene tyrosine-protein kinase Src; Pp60(src); P60-Src; C-src TK; C-Src
Click to Show/Hide
|
|||||
Representative Drug(s) | Dacomitinib | Drug Info | IC50 = 110 nM | [17] | ||
Co-Target Name | Tyrosine-protein kinase BTK (ATK) | Successful Target | ||||
UniProt ID | BTK_HUMAN | |||||
Gene Name | BTK | |||||
Synonyms |
Bruton's tyrosine kinase; Bruton tyrosine kinase; BPK; B-cell progenitor kinase; B cell progenitor kinase; Agammaglobulinemia tyrosine kinase; Agammaglobulinaemia tyrosine kinase; AGMX1
Click to Show/Hide
|
|||||
Representative Drug(s) | CI-1033 | Drug Info | IC50 = 185 nM | [18] | ||
Co-Target Name | Vascular endothelial growth factor receptor 2 (KDR) | Successful Target | ||||
UniProt ID | VGFR2_HUMAN | |||||
Gene Name | KDR | |||||
Synonyms |
VEGFR2; VEGFR-2; VEGF-2 receptor; Protein-tyrosine kinase receptor flk-1; Kinase insert domain receptor; Fetal liver kinase 1; FLK1; FLK-1; CD309
Click to Show/Hide
|
|||||
Representative Drug(s) | CUDC-101 | Drug Info | IC50 = 849 nM | Click to Show More | [8] | |
2 | HKI-272 | Drug Info | IC50 = 858.2 nM | [2] | ||
Co-Target Name | Voltage-gated potassium channel Kv11.1 (KCNH2) | Successful Target | ||||
UniProt ID | KCNH2_HUMAN | |||||
Gene Name | KCNH2 | |||||
Synonyms |
hERG1; hERG-1; Voltage-gated potassium channel subunit Kv11.1; Potassium voltage-gated channel subfamily H member 2; HERG K+ channel; HERG; H-ERG; Ether-a-go-go-related protein 1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go related protein 1; Ether-a-go-go related gene potassium channel 1; Eag related protein 1; Eag homolog; ERG-1; ERG
Click to Show/Hide
|
|||||
Representative Drug(s) | Lapatinib | Drug Info | IC50 = 1000 nM | [22] | ||
Co-Target Name | Erbb3 tyrosine kinase receptor (Erbb-3) | Clinical trial Target | ||||
UniProt ID | ERBB3_HUMAN | |||||
Gene Name | ERBB3 | |||||
Synonyms |
Tyrosine kinase-type cell surface receptor HER3; Receptor tyrosine-protein kinase erbB-3; Proto-oncogene-like protein c-ErbB-3; HER3; C-erbB3; C-erbB-3 protein
Click to Show/Hide
|
|||||
Representative Drug(s) | AZD8931 | Drug Info | IC50 = 4 nM | [23] | ||
Co-Target Name | Histone deacetylase 6 (HDAC6) | Clinical trial Target | ||||
UniProt ID | HDAC6_HUMAN | |||||
Gene Name | HDAC6 | |||||
Synonyms |
KIAA0901; JM21; HD6
Click to Show/Hide
|
|||||
Representative Drug(s) | CUDC-101 | Drug Info | IC50 = 5.1 nM | [8] | ||
Co-Target Name | Histone deacetylase 3 (HDAC3) | Clinical trial Target | ||||
UniProt ID | HDAC3_HUMAN | |||||
Gene Name | HDAC3 | |||||
Synonyms |
SMAP45; RPD32; RPD3-2; HD3
Click to Show/Hide
|
|||||
Representative Drug(s) | CUDC-101 | Drug Info | IC50 = 9.1 nM | [8] | ||
Co-Target Name | Histone deacetylase 2 (HDAC2) | Clinical trial Target | ||||
UniProt ID | HDAC2_HUMAN | |||||
Gene Name | HDAC2 | |||||
Synonyms |
HD2
Click to Show/Hide
|
|||||
Representative Drug(s) | CUDC-101 | Drug Info | IC50 = 12.6 nM | [8] | ||
Co-Target Name | Histone deacetylase 4 (HDAC4) | Clinical trial Target | ||||
UniProt ID | HDAC4_HUMAN | |||||
Gene Name | HDAC4 | |||||
Synonyms |
KIAA0288; HD4
Click to Show/Hide
|
|||||
Representative Drug(s) | CUDC-101 | Drug Info | IC50 = 13.2 nM | [8] | ||
Co-Target Name | G-protein coupled bile acid receptor 1 (GPBAR1) | Clinical trial Target | ||||
UniProt ID | GPBAR_HUMAN | |||||
Gene Name | GPBAR1 | |||||
Synonyms |
hGPCR19; hBG37; TGR5; Membrane-type receptor for bile acids; M-BAR; G-protein coupled receptor GPCR19; BG37
Click to Show/Hide
|
|||||
Representative Drug(s) | Bevacizumab + Trastuzumab | Drug Info | EC50 = 580 nM | [24] | ||
Co-Target Name | Tyrosine-protein kinase Lyn (JTK8) | Clinical trial Target | ||||
UniProt ID | LYN_HUMAN | |||||
Gene Name | LYN | |||||
Synonyms |
p56Lyn; p53Lyn; V-yes-1 Yamaguchi sarcoma viral related oncogene homolog; Lck/Yes-related novel protein tyrosine kinase
Click to Show/Hide
|
|||||
Representative Drug(s) | CUDC-101 | Drug Info | IC50 = 840 nM | [8] | ||
Co-Target Name | Histone deacetylase 5 (HDAC5) | Patented-recorded Target | ||||
UniProt ID | HDAC5_HUMAN | |||||
Gene Name | HDAC5 | |||||
Synonyms |
KIAA0600; HD5; Antigen NY-CO-9
Click to Show/Hide
|
|||||
Representative Drug(s) | CUDC-101 | Drug Info | IC50 = 11.4 nM | [8] | ||
Co-Target Name | Histone deacetylase 10 (HDAC10) | Patented-recorded Target | ||||
UniProt ID | HDA10_HUMAN | |||||
Gene Name | HDAC10 | |||||
Synonyms |
Polyamine deacetylase HDAC10; HD10
Click to Show/Hide
|
|||||
Representative Drug(s) | CUDC-101 | Drug Info | IC50 = 26.1 nM | [8] | ||
Co-Target Name | B lymphocyte kinase (BLK) | Patented-recorded Target | ||||
UniProt ID | BLK_HUMAN | |||||
Gene Name | BLK | |||||
Synonyms |
p55-Blk; Tyrosine-protein kinase Blk
Click to Show/Hide
|
|||||
Representative Drug(s) | CI-1033 | Drug Info | IC50 = 29 nM | [18] | ||
Co-Target Name | Tyrosine-protein kinase BMX (BMX) | Patented-recorded Target | ||||
UniProt ID | BMX_HUMAN | |||||
Gene Name | BMX | |||||
Synonyms |
NTK38; Epithelial and endothelial tyrosine kinase; ETK; Cytoplasmic tyrosine-protein kinase BMX; Bone marrow tyrosine kinase gene in chromosome X protein
Click to Show/Hide
|
|||||
Representative Drug(s) | CI-1033 | Drug Info | IC50 = 62 nM | [18] | ||
Co-Target Name | Histone deacetylase 9 (HDAC9) | Patented-recorded Target | ||||
UniProt ID | HDAC9_HUMAN | |||||
Gene Name | HDAC9 | |||||
Synonyms |
MITR; MEF2-interacting transcription repressor MITR; KIAA0744; Histone deacetylase-related protein; Histone deacetylase 7B; HDRP; HDAC7B; HDAC7; HD9; HD7b
Click to Show/Hide
|
|||||
Representative Drug(s) | CUDC-101 | Drug Info | IC50 = 67.2 nM | [8] | ||
Co-Target Name | Histone deacetylase 8 (HDAC8) | Patented-recorded Target | ||||
UniProt ID | HDAC8_HUMAN | |||||
Gene Name | HDAC8 | |||||
Synonyms |
Histone deacetylase-8; HDACL1; HD8; CDA07
Click to Show/Hide
|
|||||
Representative Drug(s) | CUDC-101 | Drug Info | IC50 = 79.8 nM | [8] | ||
Co-Target Name | Histone deacetylase 7 (HDAC7) | Patented-recorded Target | ||||
UniProt ID | HDAC7_HUMAN | |||||
Gene Name | HDAC7 | |||||
Synonyms |
Histone deacetylase 7A; HDAC7A; HD7a; HD7
Click to Show/Hide
|
|||||
Representative Drug(s) | CUDC-101 | Drug Info | IC50 = 373 nM | [8] | ||
Co-Target Name | NIMA-related kinase 2 (NEK2) | Literature-reported Target | ||||
UniProt ID | NEK2_HUMAN | |||||
Gene Name | NEK2 | |||||
Synonyms |
Serine/threonine-protein kinase Nek2; NimA-related protein kinase 2; NimA-like protein kinase 1; Never in mitosis A-related kinase 2; NLK1; NEK2A; HSPK 21
Click to Show/Hide
|
|||||
Representative Drug(s) | HKI-272 | Drug Info | IC50 = 274 nM | [25] | ||
Co-Target Name | HLA class I histocompatibility antigen A-3 (HLA-A) | Co-Target | ||||
UniProt ID | HLAA_HUMAN | |||||
Gene Name | HLA-A | |||||
Synonyms |
HLA class I histocompatibility antigen, A alpha chain; Human leukocyte antigen A; HLA-A
Click to Show/Hide
|
|||||
Representative Drug(s) | Nelipepimut S | Drug Info | IC50 = 33.27 nM | [26] |
References | Top | ||||
---|---|---|---|---|---|
REF 1 | Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer. J Med Chem. 2019 Nov 27;62(22):10108-10123. | ||||
REF 2 | Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cyst... Bioorg Med Chem. 2007 Jun 1;15(11):3635-48. | ||||
REF 3 | Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants. J Med Chem. 2016 Mar 10;59(5):2005-24. | ||||
REF 4 | Design, synthesis and biological evaluation of novel 4-anilinoquinazolines with C-6 urea-linked side chains as inhibitors of the epidermal growth factor receptor. Bioorg Med Chem. 2013 Dec 15;21(24):7988-98. | ||||
REF 5 | Targeting EGFR/HER2 tyrosine kinases with a new potent series of 6-substituted 4-anilinoquinazoline hybrids: Design, synthesis, kinase assay, cell-based assay, and molecular docking. Bioorg Med Chem Lett. 2015 Nov 15;25(22):5147-54. | ||||
REF 6 | Structure-activity study of quinazoline derivatives leading to the discovery of potent EGFR-T790M inhibitors. Eur J Med Chem. 2015 Sep 18;102:445-63. | ||||
REF 7 | Lead generation of 1,2-dithiolanes as exon 19 and exon 21 mutant EGFR tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2019 Jun 15;29(12):1435-1439. | ||||
REF 8 | Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer. J Med Chem. 2010 Mar 11;53(5):2000-9. | ||||
REF 9 | Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma. J Med Chem. 2019 May 9;62(9):4772-4778. | ||||
REF 10 | Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry. Eur J Med Chem. 2019 May 15;170:55-72. | ||||
REF 11 | Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy. Bioorg Med Chem. 2017 Jan 1;25(1):27-37. | ||||
REF 12 | New dermatological agents for the treatment of psoriasis. J Med Chem. 2001 Feb 1;44(3):281-97. | ||||
REF 13 | Irreversible protein kinase inhibitors: balancing the benefits and risks. J Med Chem. 2012 Jul 26;55(14):6243-62. | ||||
REF 14 | Discovery of N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl-4- morpholineacetamide as a novel and potent inhibitor of inosine monophosphate dehydrogenase with excellent in vivo activity. J Med Chem. 2002 May 23;45(11):2127-30. | ||||
REF 15 | Identification of trisubstituted-pyrazol carboxamide analogs as novel and potent antagonists of farnesoid X receptor. Bioorg Med Chem. 2014 Jun 1;22(11):2919-38. | ||||
REF 16 | Novel pyrrolo[2,1-f][1,2,4]triazin-4-amines: Dual inhibitors of EGFR and HER2 protein tyrosine kinases. Bioorg Med Chem Lett. 2011 Jan 15;21(2):781-5. | ||||
REF 17 | Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family. J Med Chem. 2016 Sep 8;59(17):8103-24. | ||||
REF 18 | Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase. Bioorg Med Chem Lett. 2008 Nov 15;18(22):5916-9. | ||||
REF 19 | Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epidermal growth factor receptor 1 and 2 kinases. J Med Chem. 2009 Nov 12;52(21):6527-30. | ||||
REF 20 | Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold. J Med Chem. 2011 Dec 8;54(23):8030-50. | ||||
REF 21 | Synthesis and biological evaluation of pyrimidine-based dual inhibitors of human epidermal growth factor receptor 1 (HER-1) and HER-2 tyrosine kinases. J Med Chem. 2012 Mar 22;55(6):2846-57. | ||||
REF 22 | Prediction of Thorough QT study results using action potential simulations based on ion channel screens. J Pharmacol Toxicol Methods. Nov-Dec 2014;70(3):246-54. | ||||
REF 23 | Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors. ACS Med Chem Lett. 2013 May 31;4(8):742-6. | ||||
REF 24 | Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies. J Med Chem. 2008 Mar 27;51(6):1831-41. | ||||
REF 25 | Therapeutic melting pot of never in mitosis gene a related kinase 2 (Nek2): a perspective on Nek2 as an oncology target and recent advancements in Nek2 small molecule inhibition. J Med Chem. 2014 Jul 24;57(14):5835-44. | ||||
REF 26 | Toward the quantitative prediction of T-cell epitopes: coMFA and coMSIA studies of peptides with affinity for the class I MHC molecule HLA-A*0201. J Med Chem. 2001 Oct 25;44(22):3572-81. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.